Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free INSM Stock Alerts

Insmed (INSM) Financials

Insmed logo
$121.16 +3.09 (+2.62%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$120.39 -0.77 (-0.63%)
As of 11/13/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Insmed

Annual Income Statements for Insmed

This table shows Insmed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -118 -176 -193 -324 -254 -294 -435 -482 -750 -914 -1,277
Consolidated Net Income / (Loss)		 -118 -176 -193 -324 -254 -294 -435 -482 -750 -914 -1,277
Net Income / (Loss) Continuing Operations		 -118 -176 -193 -324 -254 -294 -435 -482 -750 -914 -1,277
Total Pre-Tax Income 		-120 -176 -193 -324 -254 -293 -436 -480 -747 -910 -1,272
Total Operating Income		 -117 -173 -189 -307 -235 -265 -375 -457 -710 -878 -1,247
Total Gross Profit		 0.00 0.00 0.00 7.41 112 125 144 190 240 278 483
Total Revenue		 0.00 0.00 0.00 9.84 136 164 188 245 305 364 606
Operating Revenue		 0.00 - 0.00 9.84 136 164 188 245 305 364 606
Total Cost of Revenue		 0.00 0.00 0.00 2.42 24 40 44 55 66 86 123
Operating Cost of Revenue		 - 0.00 0.00 2.42 24 40 44 55 66 86 123
Total Operating Expenses		 117 173 189 315 348 390 519 648 949 1,156 1,730
Selling, General & Admin Expense		 43 51 79 168 211 204 234 266 345 461 701
Research & Development Expense		 74 123 110 145 132 181 273 398 571 598 771
Amortization Expense		 - 0.00 0.00 1.25 4.99 5.00 5.05 5.05 5.05 5.05 6.00
Other Special Charges / (Income)		 - - - - 0.00 0.00 7.33 -21 29 92 252
Total Other Income / (Expense), net		 -2.92 -3.38 -5.63 -17 -18 -27 -61 -21 -37 -32 -25
Interest Expense		 2.89 3.50 5.93 28 28 30 58 26 82 85 84
Interest & Investment Income		 - - - 10 9.92 1.70 - 11 42 53 61
Other Income / (Expense), net		 -0.03 0.12 0.30 0.60 -0.53 0.41 -3.33 -5.94 2.18 -0.21 -1.84
Income Tax Expense		 -1.97 0.10 -0.27 0.20 0.78 1.40 -1.76 1.38 2.56 3.71 5.03
Basic Earnings per Share		 ($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) ($3.88) ($3.91) ($5.34) ($5.57) ($6.42)
Weighted Average Basic Shares Outstanding		 58.63M 61.89M 66.58M 76.89M 84.56M 97.61M 112.11M 123.04M 140.43M 164.04M 199.01M
Diluted Earnings per Share		 ($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) ($3.88) ($3.91) ($5.34) ($5.57) ($6.42)
Weighted Average Diluted Shares Outstanding		 58.63M 61.89M 66.58M 76.89M 84.56M 97.61M 112.11M 123.04M 140.43M 164.04M 199.01M
Weighted Average Basic & Diluted Shares Outstanding		 58.63M 61.89M 66.58M 76.89M 84.56M 97.61M 118.90M 136.41M 148.49M 181.00M 215.55M

Quarterly Income Statements for Insmed

This table shows Insmed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -157 -301 -221 -234 -257 -322 -370 -328 -164 -13 -100
Consolidated Net Income / (Loss)		 -157 -301 -221 -78 -257 -322 -370 -328 -164 -13 -100
Net Income / (Loss) Continuing Operations		 -157 -301 -221 -236 -257 -322 -370 -328 -164 -13 -100
Total Pre-Tax Income 		-157 -300 -220 -234 -256 -320 -369 -327 -162 -11 -98
Total Operating Income		 -146 -289 -213 -230 -248 -313 -366 -320 -153 -1.55 -89
Total Gross Profit		 58 69 72 78 72 79 113 220 259 358 446
Total Revenue		 76 90 93 104 93 107 142 264 306 425 524
Operating Revenue		 76 90 93 104 93 107 142 264 306 425 524
Total Cost of Revenue		 17 21 21 26 21 28 29 44 47 67 78
Operating Cost of Revenue		 17 21 21 26 21 28 29 44 47 67 78
Total Operating Expenses		 204 358 286 309 320 392 479 539 412 360 536
Selling, General & Admin Expense		 93 107 119 143 148 155 186 212 247 247 253
Research & Development Expense		 121 147 151 180 153 177 186 255 209 210 270
Amortization Expense		 1.26 1.26 1.26 1.26 1.26 1.26 1.54 1.94 2.08 2.08 5.05
Other Special Charges / (Income)		 -12 104 15 -15 18 59 105 70 -47 -100 7.54
Total Other Income / (Expense), net		 -11 -11 -6.08 -3.25 -7.53 -7.57 -2.70 -9.28 -8.78 -9.83 -8.28
Interest Expense		 21 21 21 22 22 21 20 - 20 20 20
Interest & Investment Income		 8.78 10 17 17 14 13 18 - 12 11 11
Other Income / (Expense), net		 1.26 0.12 -2.01 1.05 0.13 0.45 -0.60 -1.82 -0.74 -0.53 1.06
Income Tax Expense		 0.59 0.84 1.01 1.27 0.91 1.24 1.32 1.55 1.47 1.87 2.67
Basic Earnings per Share		 ($1.06) ($1.94) ($1.27) ($1.30) ($1.42) ($1.70) ($1.75) ($1.55) ($0.76) ($0.06) ($0.46)
Weighted Average Basic Shares Outstanding		 148.46M 154.70M 173.72M 164.04M 180.86M 189.30M 211.76M 199.01M 215.47M 217.35M 218.79M
Diluted Earnings per Share		 ($1.06) ($1.94) ($1.27) ($1.30) ($1.42) ($1.70) ($1.75) ($1.55) ($0.76) ($0.06) ($0.46)
Weighted Average Diluted Shares Outstanding		 148.46M 154.70M 173.72M 164.04M 180.86M 189.30M 211.76M 199.01M 215.47M 217.35M 218.79M
Weighted Average Basic & Diluted Shares Outstanding		 148.60M 171.85M 178.90M 181.00M 182.14M 211.37M 213.27M 215.55M 216.75M 218.38M 219.38M

Annual Cash Flow Statements for Insmed

This table details how cash moves in and out of Insmed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 124 -120 219 114 -7.64 45 184 357 -592 73 -46
Net Cash From Operating Activities		 -101 -147 -160 -258 -251 -219 -363 -400 -536 -684 -935
Net Cash From Continuing Operating Activities		 -101 -147 -160 -258 -251 -219 -363 -400 -536 -684 -935
Net Income / (Loss) Continuing Operations		 -118 -176 -193 -324 -254 -294 -435 -482 -750 -914 -1,277
Consolidated Net Income / (Loss)		 -118 -176 -193 -324 -254 -294 -435 -482 -750 -914 -1,277
Depreciation Expense		 1.98 2.44 2.90 3.58 5.19 9.15 9.13 5.28 5.53 5.96 10
Amortization Expense		 0.46 0.28 0.12 2.60 25 7.48 8.02 11 15 15 15
Non-Cash Adjustments To Reconcile Net Income		 16 18 19 44 37 61 105 78 204 121 145
Changes in Operating Assets and Liabilities, net		 -0.62 8.64 11 16 -63 -2.95 -51 -13 -11 89 172
Net Cash From Investing Activities		 -3.45 -4.20 -3.00 -15 -42 -6.82 -64 -35 -224 -583 -65
Net Cash From Continuing Investing Activities		 -3.45 -4.20 -3.00 -15 -42 -6.82 -64 -35 -224 -583 -65
Purchase of Property, Plant & Equipment		 -3.45 -4.20 -3.00 -13 -42 -6.24 -7.29 -9.88 -13 -22 -33
Acquisitions		 - 0.00 0.00 -1.72 0.00 -0.58 -6.70 0.00 3.42 0.00 0.00
Purchase of Investments		 - - - - 0.00 0.00 -50 -100 -589 -1,577 -2,092
Sale and/or Maturity of Investments		 - - - - - 0.00 0.00 75 375 1,016 2,090
Other Investing Activities, net		 - - - - - - - - - - -30
Net Cash From Financing Activities		 228 31 381 387 285 271 613 793 168 1,341 954
Net Cash From Continuing Financing Activities		 228 31 381 387 285 271 613 793 168 1,341 954
Repayment of Debt		 -0.25 -0.41 0.00 -72 4.50 -0.94 -253 -18 -1.22 -3.74 -1.97
Issuance of Debt		 0.00 30 0.00 450 0.00 0.00 575 350 0.00 150 0.00
Issuance of Common Equity		 223 0.00 378 0.00 261 246 270 292 152 1,084 823
Other Financing Activities, net		 5.11 1.08 3.43 8.82 20 26 21 169 17 111 133
Cash Interest Paid		 2.95 3.61 5.17 6.29 7.88 9.19 11 10 36 41 55
Cash Income Taxes Paid		 -3.01 0.09 0.17 0.15 0.34 0.81 1.56 1.72 1.96 2.50 4.14

Quarterly Cash Flow Statements for Insmed

This table details how cash moves in and out of Insmed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 113 651 -785 94 -152 881 -950 175 72 -37 -148
Net Cash From Operating Activities		 -184 -123 -181 -196 -262 -206 -220 -248 -223 -89 -36
Net Cash From Continuing Operating Activities		 -184 -123 -181 -196 -262 -206 -220 -248 -223 -89 -36
Net Income / (Loss) Continuing Operations		 -157 -301 -221 -236 -257 -322 -370 -328 -164 -13 -100
Consolidated Net Income / (Loss)		 -157 -301 -221 -236 -257 -322 -370 -328 -164 -13 -100
Depreciation Expense		 1.59 1.44 1.46 1.48 1.88 2.48 2.46 3.62 2.93 3.18 3.35
Amortization Expense		 3.79 3.74 3.43 3.69 3.76 3.62 3.56 3.99 4.14 4.19 7.21
Non-Cash Adjustments To Reconcile Net Income		 37 30 32 22 37 41 26 41 45 42 42
Changes in Operating Assets and Liabilities, net		 -69 143 2.80 12 -48 69 119 32 -111 -125 11
Net Cash From Investing Activities		 295 -6.78 -1,003 132 80 228 -762 389 266 25 -136
Net Cash From Continuing Investing Activities		 295 -6.78 -1,003 132 80 228 -762 389 266 25 -136
Purchase of Property, Plant & Equipment		 -4.68 -6.78 -3.69 -6.77 -10 -3.48 -2.42 -17 -3.48 -6.26 -5.63
Purchase of Investments		 0.00 - -1,000 -577 -631 -277 -1,185 - 0.00 -399 -395
Sale and/or Maturity of Investments		 300 - - 716 721 508 425 436 284 430 265
Net Cash From Financing Activities		 3.02 781 397 159 29 858 33 34 30 27 24
Net Cash From Continuing Financing Activities		 3.02 781 397 159 29 858 33 34 30 27 24
Other Financing Activities, net		 3.43 68 26 13 29 36 34 34 30 27 24
Effect of Exchange Rate Changes		 -0.95 -0.69 1.84 -1.51 0.90 1.01 -0.98 - -0.55 -0.29 0.27
Cash Interest Paid		 8.21 8.49 8.63 15 13 13 15 14 13 13 13
Cash Income Taxes Paid		 1.21 0.35 0.69 0.25 2.18 0.68 1.18 0.11 2.94 0.70 1.44

Annual Balance Sheets for Insmed

This table presents Insmed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 357 238 462 605 742 796 1,244 1,656 1,330 2,025 2,265
Total Current Assets		 288 168 389 519 555 623 837 1,273 929 1,622 1,794
Cash & Equivalents		 283 163 381 495 487 533 717 1,074 482 555 510
Short-Term Investments		 - - - - - - 0.00 74 298 879 920
Accounts Receivable		 - - 0.00 5.52 19 17 24 30 41 52 141
Inventories, net		 - - 0.00 7.03 28 50 67 70 83 99 132
Prepaid Expenses		 5.24 5.82 8.28 11 20 24 29 25 24 37 91
Plant, Property, & Equipment, net		 8.09 10 12 23 60 54 53 56 65 80 103
Total Noncurrent Assets		 60 60 60 63 127 119 354 327 335 324 367
Noncurrent Note & Lease Receivables		 - - - 0.00 15 10 9.26 24 21 18 16
Goodwill		 - - - - - 0.00 136 136 136 136 136
Intangible Assets		 58 58 58 59 54 49 74 69 64 59 98
Other Noncurrent Operating Assets		 2.15 1.33 1.97 4.30 58 60 84 98 115 110 118
Total Liabilities & Shareholders' Equity		 357 238 462 605 742 796 1,244 1,656 1,330 2,025 2,265
Total Liabilities		 45 83 101 396 481 520 833 1,568 1,662 1,740 1,526
Total Current Liabilities		 22 28 45 80 85 119 135 190 226 298 469
Short-Term Debt		 3.11 - - - - - - - - - 0.00
Accounts Payable		 7.47 10 15 18 13 43 125 182 215 285 456
Other Current Liabilities		 0.68 0.73 0.65 1.53 13 13 10 8.13 11 12 13
Total Noncurrent Liabilities		 23 55 56 317 395 401 698 1,378 1,436 1,442 1,057
Long-Term Debt		 22 55 56 317 336 356 567 1,125 1,155 1,103 541
Other Noncurrent Operating Liabilities		 0.57 0.69 0.77 0.00 59 45 131 253 281 339 516
Total Equity & Noncontrolling Interests		 312 154 361 208 262 276 410 88 -332 285 739
Total Preferred & Common Equity		 312 154 361 208 262 276 410 88 -332 285 739
Total Common Equity		 312 154 361 208 262 276 410 88 -332 285 739
Common Stock		 901 920 1,319 1,490 1,798 2,106 2,675 2,784 3,115 4,648 6,374
Retained Earnings		 -589 -765 -958 -1,282 -1,536 -1,831 -2,265 -2,697 -3,446 -4,360 -5,637
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.07 -0.00 -0.01 -0.01 0.19 0.97 0.76 -0.75 -2.29 1.46

Quarterly Balance Sheets for Insmed

This table presents Insmed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 1,439 1,325 1,159 1,810 2,053 1,803 2,480 2,361 2,076 2,103 2,226
Total Current Assets		 1,052 927 759 1,418 1,650 1,403 2,082 1,932 1,613 1,634 1,707
Cash & Equivalents		 613 487 596 1,247 461 403 1,284 335 582 545 397
Short-Term Investments		 305 299 0.00 0.00 1,006 796 572 1,345 641 616 750
Accounts Receivable		 31 36 37 40 42 48 55 65 179 215 259
Inventories, net		 77 78 83 90 98 101 108 121 133 142 164
Prepaid Expenses		 26 27 43 41 41 55 62 66 78 116 137
Plant, Property, & Equipment, net		 62 65 69 73 75 88 90 90 103 107 108
Total Noncurrent Assets		 325 334 332 319 328 312 308 339 360 361 411
Noncurrent Note & Lease Receivables		 22 22 20 20 19 18 17 16 15 14 14
Goodwill		 136 136 136 136 136 136 136 136 136 136 136
Intangible Assets		 66 65 62 61 60 57 56 85 96 93 138
Other Noncurrent Operating Assets		 100 111 113 102 113 101 99 102 113 118 123
Total Liabilities & Shareholders' Equity		 1,439 1,325 1,159 1,810 2,053 1,803 2,480 2,361 2,076 2,103 2,226
Total Liabilities		 1,595 1,614 1,624 1,771 1,570 1,704 1,230 1,415 1,371 1,345 1,500
Total Current Liabilities		 204 197 421 524 259 239 312 417 361 439 597
Short-Term Debt		 - - 224 224 - - - - - - 10
Accounts Payable		 198 188 189 291 249 233 305 410 353 429 575
Other Current Liabilities		 6.60 8.95 7.30 8.86 11 6.56 6.66 7.38 8.45 9.82 12
Total Noncurrent Liabilities		 1,391 1,418 1,203 1,247 1,310 1,464 918 998 1,010 906 903
Long-Term Debt		 1,140 1,148 939 947 955 1,105 539 540 542 544 545
Other Noncurrent Operating Liabilities		 251 270 264 300 356 359 380 458 468 363 358
Total Equity & Noncontrolling Interests		 -156 -289 -465 39 483 99 1,250 946 705 757 726
Total Preferred & Common Equity		 -156 -289 -465 39 483 99 1,250 946 705 757 726
Total Common Equity		 -156 -289 -465 39 483 99 1,250 946 705 757 726
Common Stock		 2,947 2,973 3,140 3,945 4,607 4,717 6,186 6,252 6,505 6,574 6,640
Retained Earnings		 -3,101 -3,260 -3,603 -3,904 -4,124 -4,617 -4,938 -5,308 -5,800 -5,813 -5,914
Accumulated Other Comprehensive Income / (Loss)		 -1.25 -2.08 -1.64 -2.83 0.55 -0.90 1.73 2.00 0.00 -3.37 -0.04

Annual Metrics And Ratios for Insmed

This table displays calculated financial ratios and metrics derived from Insmed's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 1,287.56% 20.48% 14.63% 30.19% 24.39% 19.17% 66.73%
EBITDA Growth		 -34.19% -48.20% -8.82% -61.94% 31.51% -20.57% -45.56% -23.72% -53.66% -24.86% -42.59%
EBIT Growth		 -34.74% -47.44% -8.85% -62.62% 23.13% -12.32% -42.89% -22.42% -52.71% -24.14% -42.14%
NOPAT Growth		 -34.49% -47.58% -8.95% -62.68% 23.46% -12.75% -41.42% -21.92% -55.17% -23.76% -41.96%
Net Income Growth		 -49.30% -49.15% -9.29% -68.33% 21.57% -15.63% -47.80% -10.79% -55.66% -21.91% -39.73%
EPS Growth		 -9.78% -41.09% -1.40% -46.02% 28.67% 0.00% -28.90% -0.77% -36.57% -4.31% -15.26%
Operating Cash Flow Growth		 -56.33% -45.69% -8.80% -61.62% 2.84% 12.49% -65.63% -10.22% -33.91% -27.53% -36.72%
Free Cash Flow Firm Growth		 -31.97% -35.29% -6.07% -73.05% -17.04% 28.63% -113.44% 53.18% -171.58% -10.95% -45.74%
Invested Capital Growth		 4.04% -13.49% -24.04% -16.10% 270.34% -9.75% 111.40% -69.12% -33.85% -204.94% -233.09%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 35.66% -2.54% 8.47% 1.31% 8.69% 6.05% 35.66%
EBITDA Q/Q Growth		 -8.73% -25.34% 0.97% -7.38% 22.47% -35.07% -8.51% -6.43% -3.83% -5.39% -7.88%
EBIT Q/Q Growth		 -8.80% -24.80% 0.93% -7.88% 14.60% -21.44% -2.05% -11.72% -3.73% -6.46% -7.94%
NOPAT Q/Q Growth		 -8.82% -24.80% 0.89% -7.85% 14.73% -21.79% -1.23% -12.94% -3.92% -6.31% -7.72%
Net Income Q/Q Growth		 -13.00% -26.71% 1.54% -8.79% 13.17% -20.10% -2.54% -10.85% -3.58% 10.54% -7.85%
EPS Q/Q Growth		 -8.02% -27.23% 7.37% -7.93% 17.31% -17.12% 1.02% -7.12% -1.14% -0.36% -4.05%
Operating Cash Flow Q/Q Growth		 -16.98% -26.15% 5.75% -9.30% 9.32% -11.37% -5.01% -4.99% -5.44% -10.53% -5.84%
Free Cash Flow Firm Q/Q Growth		 -9.53% -18.90% 5.05% -10.72% 4.57% -1.42% -4.92% 43.44% -53.82% -10.57% -18.99%
Invested Capital Q/Q Growth		 1.27% -10.21% -22.94% -16.65% 10.84% -16.74% -2.62% -73.12% -40.53% -51.93% 22.90%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 75.36% 82.26% 75.75% 76.57% 77.53% 78.52% 76.43% 79.73%
EBITDA Margin		 0.00% 0.00% 0.00% -3,056.02% -150.84% -150.96% -191.70% -182.17% -225.04% -235.80% -201.71%
Operating Margin		 0.00% 0.00% 0.00% -3,124.94% -172.38% -161.32% -199.03% -186.39% -232.51% -241.47% -205.59%
EBIT Margin		 0.00% 0.00% 0.00% -3,118.82% -172.77% -161.07% -200.80% -188.81% -231.79% -241.46% -205.90%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -3,297.17% -186.37% -178.87% -230.63% -196.26% -245.59% -251.24% -210.54%
Tax Burden Percent		 98.36% 100.06% 99.86% 100.06% 100.31% 100.48% 99.60% 100.29% 100.34% 100.41% 100.40%
Interest Burden Percent		 102.24% 101.67% 102.28% 105.65% 107.54% 110.52% 115.32% 103.65% 105.59% 103.63% 101.85%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -659.80% -235.35% -177.13% -169.57% -232.69% -921.05% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -616.50% -181.01% -111.00% -78.20% -88.10% -1,064.77% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 545.88% 127.11% 67.72% 42.92% 39.46% 1,535.52% 0.00% 0.00%
Return on Equity (ROE)		 -47.47% -75.62% -74.74% -113.92% -108.24% -109.42% -126.66% -193.22% 614.47% 3,926.49% -249.28%
Cash Return on Invested Capital (CROIC)		 -159.39% -226.74% -294.66% -642.29% -350.31% -166.89% -241.12% -127.07% -880.29% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -57.52% -35.01% -34.43% -37.11% -31.95% -47.38% -52.35% -58.21%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -60.81% -37.77% -38.23% -42.62% -33.21% -50.20% -54.47% -59.53%
Return on Common Equity (ROCE)		 -47.47% -75.62% -74.74% -113.92% -108.24% -109.42% -126.66% -193.22% 614.47% 3,926.49% -249.28%
Return on Equity Simple (ROE_SIMPLE)		 -37.92% -114.11% -53.36% -155.70% -97.20% -106.60% -105.89% -547.50% 225.83% -320.20% 0.00%
Net Operating Profit after Tax (NOPAT)		 -82 -121 -132 -215 -165 -186 -263 -320 -497 -615 -873
NOPAT Margin		 0.00% 0.00% 0.00% -2,187.46% -120.67% -112.92% -139.32% -130.47% -162.75% -169.03% -143.92%
Net Nonoperating Expense Percent (NNEP)		 -18.33% -30.03% -27.88% -43.30% -54.34% -66.13% -91.37% -144.59% 143.72% 1,346.16% -66.26%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -26.39% -60.33% -44.27% -68.19%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 24.64% 17.74% 24.25% 23.43% 22.47% 21.48% 23.57% 20.27%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 1,710.40% 154.47% 123.84% 124.31% 108.33% 112.87% 126.78% 115.62%
R&D to Revenue		 0.00% 0.00% 0.00% 1,477.20% 96.51% 110.18% 144.72% 162.02% 187.09% 164.52% 127.15%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 3,200.31% 254.64% 237.07% 275.60% 263.92% 311.02% 317.90% 285.32%
Earnings before Interest and Taxes (EBIT)		 -118 -173 -189 -307 -236 -265 -378 -463 -707 -878 -1,249
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -115 -171 -186 -301 -206 -248 -361 -447 -687 -858 -1,223
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.60 5.30 6.61 4.86 8.15 12.29 7.86 30.78 0.00 43.28 50.23
Price to Tangible Book Value (P/TBV)		 4.43 8.50 7.89 6.76 10.26 14.96 16.08 0.00 0.00 136.30 73.47
Price to Revenue (P/Rev)		 0.00 0.00 0.00 102.84 15.63 20.63 17.11 11.03 14.53 33.96 61.21
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 16.01 15.23 58.16 28.00 17.99 32.33 14.39 41.34 111.97 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 84.69 14.52 19.55 16.05 10.94 15.75 33.05 59.74
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.08 0.35 0.15 1.52 1.28 1.29 1.38 12.79 -3.48 3.87 0.73
Long-Term Debt to Equity		 0.07 0.35 0.15 1.52 1.28 1.29 1.38 12.79 -3.48 3.87 0.73
Financial Leverage		 -0.79 -0.78 -0.84 -0.89 -0.70 -0.61 -0.55 -0.45 -1.44 -0.95 -1.19
Leverage Ratio		 1.18 1.28 1.36 1.87 2.87 2.86 2.97 5.82 -12.24 -72.08 4.19
Compound Leverage Factor		 1.21 1.30 1.39 1.98 3.08 3.16 3.43 6.03 -12.92 -74.70 4.27
Debt to Total Capital		 7.46% 26.18% 13.34% 60.32% 56.21% 56.36% 57.99% 92.75% 140.31% 79.45% 42.26%
Short-Term Debt to Total Capital		 0.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 6.54% 26.18% 13.34% 60.32% 56.21% 56.36% 57.99% 92.75% 140.31% 79.45% 42.26%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 92.54% 73.82% 86.66% 39.68% 43.79% 43.64% 42.01% 7.25% -40.31% 20.55% 57.74%
Debt to EBITDA		 -0.22 -0.32 -0.30 -1.05 -1.63 -1.44 -1.57 -2.52 -1.68 -1.29 -0.44
Net Debt to EBITDA		 2.24 0.63 1.75 0.59 0.74 0.71 0.55 0.05 -0.55 0.39 0.73
Long-Term Debt to EBITDA		 -0.19 -0.32 -0.30 -1.05 -1.63 -1.44 -1.57 -2.52 -1.68 -1.29 -0.44
Debt to NOPAT		 -0.31 -0.45 -0.42 -1.47 -2.04 -1.92 -2.16 -3.52 -2.33 -1.79 -0.62
Net Debt to NOPAT		 3.13 0.89 2.46 0.83 0.92 0.95 0.76 0.07 -0.75 0.54 1.02
Long-Term Debt to NOPAT		 -0.27 -0.45 -0.42 -1.47 -2.04 -1.92 -2.16 -3.52 -2.33 -1.79 -0.62
Altman Z-Score		 12.50 -0.31 10.83 -2.22 -0.34 0.56 -0.40 -1.23 -2.92 0.78 10.26
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.94 6.02 8.72 6.51 6.51 5.24 6.19 6.69 4.12 5.45 3.83
Quick Ratio		 12.71 5.81 8.54 6.28 5.94 4.62 5.48 6.19 3.64 4.99 3.35
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -84 -114 -121 -209 -245 -175 -373 -175 -475 -527 -768
Operating Cash Flow to CapEx		 -2,915.46% -3,493.05% -5,318.79% -1,970.79% -593.00% -3,515.19% -4,984.25% -4,053.85% -4,035.57% -3,119.47% -2,871.58%
Free Cash Flow to Firm to Interest Expense		 -29.19 -32.62 -20.43 -7.57 -8.85 -5.92 -6.42 -6.61 -5.81 -6.20 -9.16
Operating Cash Flow to Interest Expense		 -34.86 -41.94 -26.94 -9.32 -9.05 -7.42 -6.25 -15.14 -6.56 -8.05 -11.16
Operating Cash Flow Less CapEx to Interest Expense		 -36.05 -43.14 -27.45 -9.79 -10.57 -7.63 -6.37 -15.52 -6.73 -8.31 -11.55
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.02 0.20 0.21 0.18 0.17 0.20 0.22 0.28
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 11.03 9.19 9.21 9.08 8.61 7.80 6.29
Inventory Turnover		 0.00 0.00 0.00 0.00 1.37 1.02 0.76 0.81 0.86 0.94 1.07
Fixed Asset Turnover		 0.00 0.00 0.00 0.56 3.30 2.88 3.53 4.48 5.01 5.00 6.63
Accounts Payable Turnover		 0.00 0.00 0.00 0.15 1.57 1.42 0.53 0.36 0.33 0.34 0.33
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 33.09 39.73 39.62 40.21 42.40 46.77 58.04
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 266.42 356.58 481.96 453.32 426.30 387.01 342.39
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 2,441.27 233.10 256.49 693.94 1,016.84 1,105.20 1,064.66 1,100.41
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -2,441.27 66.41 139.82 -172.35 -523.30 -636.51 -630.88 -699.97
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 54 47 35 30 110 99 210 65 43 -45 -150
Invested Capital Turnover		 0.00 0.00 0.00 0.30 1.95 1.57 1.22 1.78 5.66 -342.80 -6.21
Increase / (Decrease) in Invested Capital		 2.10 -7.28 -11 -5.71 80 -11 111 -145 -22 -88 -105
Enterprise Value (EV)		 864 711 2,063 833 1,982 3,215 3,024 2,684 4,808 12,021 36,229
Market Capitalization		 1,122 819 2,388 1,011 2,134 3,391 3,224 2,707 4,433 12,351 37,118
Book Value per Share		 $5.04 $2.50 $4.71 $2.70 $2.93 $2.71 $3.47 $0.65 ($2.32) $1.60 $3.46
Tangible Book Value per Share		 $4.10 $1.56 $3.95 $1.94 $2.33 $2.22 $1.69 ($0.86) ($3.72) $0.51 $2.37
Total Capital		 337 209 417 525 598 632 977 1,213 823 1,389 1,280
Total Debt		 25 55 56 317 336 356 567 1,125 1,155 1,103 541
Total Long-Term Debt		 22 55 56 317 336 356 567 1,125 1,155 1,103 541
Net Debt		 -258 -108 -326 -179 -151 -176 -200 -23 375 -330 -889
Capital Expenditures (CapEx)		 3.45 4.20 3.00 13 42 6.24 7.29 9.88 13 22 33
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -22 -36 -56 -17 -29 -15 -65 -77 -110 -105
Debt-free Net Working Capital (DFNWC)		 269 140 345 439 470 504 702 1,083 703 1,324 1,325
Net Working Capital (NWC)		 266 140 345 439 470 504 702 1,083 703 1,324 1,325
Net Nonoperating Expense (NNE)		 36 55 60 109 90 108 172 161 253 299 404
Net Nonoperating Obligations (NNO)		 -258 -108 -326 -179 -151 -176 -200 -23 375 -330 -889
Total Depreciation and Amortization (D&A)		 2.44 2.72 3.02 6.18 30 17 17 16 21 21 25
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -567.95% -12.81% -17.44% -7.91% -26.55% -25.23% -30.16% -17.27%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 4,465.83% 344.37% 306.60% 372.42% 441.45% 230.48% 364.07% 218.55%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 4,465.83% 344.37% 306.60% 372.42% 441.45% 230.48% 364.07% 218.55%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) ($3.88) ($3.91) ($5.34) ($5.57) ($6.42)
Adjusted Weighted Average Basic Shares Outstanding		 61.86M 62.02M 76.62M 77.54M 89.78M 103.04M 112.11M 123.04M 140.43M 164.04M 199.01M
Adjusted Diluted Earnings per Share		 ($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) ($3.88) ($3.91) ($5.34) ($5.57) ($6.42)
Adjusted Weighted Average Diluted Shares Outstanding		 61.86M 62.02M 76.62M 77.54M 89.78M 103.04M 112.11M 123.04M 140.43M 164.04M 199.01M
Adjusted Basic & Diluted Earnings per Share		 ($2.02) ($2.85) ($2.89) ($4.22) ($3.01) ($3.01) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.63M 61.89M 66.58M 76.89M 84.56M 97.61M 118.90M 136.41M 148.49M 181.00M 215.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -82 -121 -132 -215 -165 -186 -257 -335 -477 -551 -696
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -2,187.46% -120.67% -112.92% -136.60% -136.41% -156.17% -151.39% -114.83%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -3,295.13% -185.80% -178.02% -231.57% -195.69% -244.76% -250.22% -209.71%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -40.68 -49.54 -31.83 -11.08 -8.51 -8.96 -6.51 -17.52 -8.66 -10.34 -14.90
NOPAT to Interest Expense		 -28.47 -34.70 -22.32 -7.77 -5.94 -6.28 -4.51 -12.10 -6.08 -7.24 -10.42
EBIT Less CapEx to Interest Expense		 -41.88 -50.74 -32.34 -11.55 -10.04 -9.17 -6.63 -17.89 -8.82 -10.60 -15.29
NOPAT Less CapEx to Interest Expense		 -29.66 -35.90 -22.83 -8.24 -7.47 -6.49 -4.64 -12.48 -6.24 -7.50 -10.80
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Insmed

This table displays calculated financial ratios and metrics derived from Insmed's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 - - - - - - - - 215,551,896.00 216,752,451.00 218,381,503.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 215,551,896.00 216,752,451.00 218,381,503.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.76 -0.06 -0.46
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 15.77% 16.98% 18.15% 24.79% 22.94% 18.90% 52.36% 152.62% 229.62% 296.11% 268.43%
EBITDA Growth		 3.13% -23.07% -48.16% -31.41% -74.53% -8.01% -71.26% -39.65% 39.35% 101.73% 78.44%
EBIT Growth		 2.72% -22.52% -46.18% -30.48% -71.94% -8.18% -70.17% -39.82% 37.88% 99.33% 75.91%
NOPAT Growth		 1.79% -22.66% -44.53% -29.25% -70.54% -8.30% -71.49% -38.77% 38.21% 99.51% 75.58%
Net Income Growth		 -96.65% -22.79% -38.75% 57.83% -63.33% -7.01% -67.79% -39.46% 36.25% 95.88% 72.89%
EPS Growth		 9.40% -8.99% -14.41% -1.56% -33.96% 12.37% -37.80% -19.23% 46.48% 96.47% 73.71%
Operating Cash Flow Growth		 -25.79% -0.13% -32.70% -49.81% -42.41% -67.19% -21.47% -26.34% 15.01% 56.79% 83.41%
Free Cash Flow Firm Growth		 -352.69% -406.04% -172.05% 28.72% 34.56% -88.65% -91.83% -62.09% -66.50% -12.34% -329.90%
Invested Capital Growth		 15.63% -155.37% -141.08% -204.94% -95.35% -86.67% -556.38% -233.09% 393.15% 305.33% 169.18%
Revenue Q/Q Growth		 -9.79% 19.66% 3.41% 11.79% -11.12% 15.72% 32.52% 85.36% 15.96% 39.06% 23.25%
EBITDA Q/Q Growth		 22.99% -104.52% 25.86% -6.48% -8.10% -26.39% -17.72% 12.93% 53.18% 103.60% -1,570.48%
EBIT Q/Q Growth		 18.09% -100.48% 25.50% -6.47% -8.13% -25.97% -17.34% 12.28% 52.09% 98.65% -4,147.86%
NOPAT Q/Q Growth		 18.38% -98.55% 26.12% -7.96% -7.69% -26.09% -16.98% 12.64% 52.05% 98.99% -5,673.19%
Net Income Q/Q Growth		 -68.86% 4.32% 26.64% 64.42% -227.04% -25.37% -15.03% 11.23% 50.21% 91.90% -657.58%
EPS Q/Q Growth		 17.19% -83.02% 34.54% -2.36% -9.23% -19.72% -2.94% 11.43% 50.97% 92.11% -666.67%
Operating Cash Flow Q/Q Growth		 -40.68% 33.19% -47.14% -8.33% -33.73% 21.56% -6.90% -12.67% 10.04% 60.12% 58.95%
Free Cash Flow Firm Q/Q Growth		 -12.57% 14.26% 52.11% -54.19% -3.35% -147.17% 51.30% -30.29% -6.16% -66.77% -86.37%
Invested Capital Q/Q Growth		 139.24% -135.73% 19.19% -51.93% 110.60% -1,534.72% -184.14% 22.90% 115.69% 497.35% -4.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 76.88% 76.79% 77.34% 74.96% 77.08% 73.86% 79.37% 83.24% 84.50% 84.20% 85.09%
EBITDA Margin		 -183.92% -314.36% -225.37% -214.67% -261.10% -285.18% -253.33% -118.99% -48.04% 1.24% -14.83%
Operating Margin		 -192.72% -319.80% -228.45% -220.61% -267.33% -291.28% -257.13% -121.19% -50.11% -0.36% -17.04%
EBIT Margin		 -191.05% -320.09% -230.60% -219.61% -267.18% -290.86% -257.55% -121.88% -50.35% -0.49% -16.84%
Profit (Net Income) Margin		 -416.14% -332.75% -236.04% -75.12% -276.42% -299.48% -259.95% -124.50% -53.46% -3.11% -19.13%
Tax Burden Percent		 200.75% 100.28% 100.46% 33.49% 100.36% 100.39% 100.36% 100.47% 100.90% 116.43% 102.73%
Interest Burden Percent		 108.50% 103.66% 101.89% 102.14% 103.09% 102.57% 100.57% 101.67% 105.22% 547.04% 110.58%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -444.30% -4,973.00% -2,577.92% 0.00% -1,326.37% 0.00% 0.00% 0.00% -2,029.59% -8.03% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -504.87% -5,107.30% -2,484.04% 0.00% -1,361.40% 0.00% 0.00% 0.00% -2,015.09% -6.77% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 694.74% 6,399.51% 1,939.39% 0.00% 1,761.70% 0.00% 0.00% 0.00% 1,944.09% 6.53% 0.00%
Return on Equity (ROE)		 250.44% 1,426.50% -638.53% 3,926.49% 435.34% -160.54% -165.69% -249.28% -85.50% -1.50% -72.45%
Cash Return on Invested Capital (CROIC)		 -531.09% 0.00% 0.00% 0.00% -1,095.04% 0.00% 0.00% 0.00% -5,825.42% -566.94% -537.69%
Operating Return on Assets (OROA)		 -45.04% -64.74% -46.83% -47.61% -68.74% -53.98% -52.17% -34.46% -21.28% -0.24% -11.16%
Return on Assets (ROA)		 -98.09% -67.30% -47.93% -16.29% -71.12% -55.58% -52.66% -35.20% -22.59% -1.55% -12.68%
Return on Common Equity (ROCE)		 250.44% 1,426.50% -638.53% 3,926.49% 435.34% -160.54% -165.69% -249.28% -85.50% -1.50% -72.45%
Return on Equity Simple (ROE_SIMPLE)		 194.49% -2,472.53% -211.28% 0.00% -1,021.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -102 -202 -149 -161 -174 -219 -256 -224 -107 -1.08 -63
NOPAT Margin		 -134.91% -223.86% -159.91% -154.43% -187.13% -203.89% -179.99% -84.83% -35.08% -0.25% -11.93%
Net Nonoperating Expense Percent (NNEP)		 60.57% 134.29% -93.89% -372.94% 35.03% -14.73% -13.77% -17.16% -14.50% -1.26% -4.36%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -11.61% -14.42% -12.25% -17.25% -17.49% -8.61% -0.08% -4.88%
Cost of Revenue to Revenue		 23.12% 23.21% 22.66% 25.04% 22.92% 26.14% 20.63% 16.76% 15.50% 15.80% 14.91%
SG&A Expenses to Revenue		 123.31% 117.96% 127.30% 136.45% 158.95% 144.08% 130.94% 80.53% 80.81% 58.16% 48.25%
R&D to Revenue		 160.37% 162.44% 161.42% 172.08% 164.37% 164.96% 130.96% 96.61% 68.47% 49.36% 51.48%
Operating Expenses to Revenue		 269.60% 396.59% 305.79% 295.58% 344.40% 365.14% 336.50% 204.43% 134.61% 84.57% 102.13%
Earnings before Interest and Taxes (EBIT)		 -144 -289 -215 -229 -248 -312 -367 -322 -154 -2.08 -88
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -139 -284 -211 -224 -242 -306 -361 -314 -147 5.29 -78
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 256.49 25.95 43.28 139.26 14.67 32.19 50.23 50.01 30.51 34.32
Price to Tangible Book Value (P/TBV)		 0.00 0.00 43.65 136.30 0.00 17.33 41.99 73.47 74.49 43.78 55.19
Price to Revenue (P/Rev)		 12.30 30.30 36.58 33.96 36.24 46.04 68.10 61.21 43.01 20.31 16.40
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 43.30 0.00 0.00 0.00 2,871.45 0.00 0.00 0.00 1,467.57 159.87 180.68
Enterprise Value to Revenue (EV/Rev)		 14.10 30.07 35.08 33.05 35.99 42.73 65.54 59.74 42.18 19.77 16.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -2.50 30.17 1.98 3.87 11.14 0.43 0.57 0.73 0.77 0.72 0.76
Long-Term Debt to Equity		 -2.02 24.39 1.98 3.87 11.14 0.43 0.57 0.73 0.77 0.72 0.75
Financial Leverage		 -1.38 -1.25 -0.78 -0.95 -1.29 -1.08 -1.16 -1.19 -0.96 -0.96 -1.04
Leverage Ratio		 -5.25 -27.79 17.41 -72.08 -8.10 3.33 3.09 4.19 4.82 2.28 2.74
Compound Leverage Factor		 -5.70 -28.81 17.74 -73.63 -8.35 3.41 3.11 4.26 5.08 12.49 3.03
Debt to Total Capital		 166.55% 96.79% 66.39% 79.45% 91.77% 30.11% 36.34% 42.26% 43.48% 41.78% 43.32%
Short-Term Debt to Total Capital		 32.10% 18.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.80%
Long-Term Debt to Total Capital		 134.45% 78.24% 66.39% 79.45% 91.77% 30.11% 36.34% 42.26% 43.48% 41.78% 42.52%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -66.55% 3.21% 33.61% 20.55% 8.23% 69.89% 63.66% 57.74% 56.52% 58.22% 56.68%
Debt to EBITDA		 -1.68 -1.57 -1.17 -1.29 -1.15 -0.55 -0.48 -0.44 -0.48 -0.67 -1.04
Net Debt to EBITDA		 -0.82 0.10 0.63 0.39 0.10 1.34 1.01 0.73 0.60 0.76 1.11
Long-Term Debt to EBITDA		 -1.36 -1.27 -1.17 -1.29 -1.15 -0.55 -0.48 -0.44 -0.48 -0.67 -1.02
Debt to NOPAT		 -2.35 -2.20 -1.65 -1.79 -1.61 -0.77 -0.67 -0.62 -0.67 -0.92 -1.41
Net Debt to NOPAT		 -1.15 0.14 0.89 0.54 0.14 1.87 1.41 1.02 0.84 1.05 1.50
Long-Term Debt to NOPAT		 -1.90 -1.78 -1.65 -1.79 -1.61 -0.77 -0.67 -0.62 -0.67 -0.92 -1.38
Altman Z-Score		 -2.71 0.60 2.62 1.84 1.81 6.75 10.20 11.62 12.39 7.66 7.40
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.80 2.71 6.37 5.45 5.86 6.68 4.63 3.83 4.47 3.72 2.86
Quick Ratio		 1.50 2.46 5.83 4.99 5.21 6.13 4.18 3.35 3.88 3.14 2.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -116 -99 -48 -73 -76 -187 -91 -119 -126 -210 -392
Operating Cash Flow to CapEx		 -3,933.21% -1,812.65% -4,904.20% -2,893.96% -2,602.66% -5,900.37% -9,088.54% -1,492.53% -6,400.52% -1,419.20% -648.18%
Free Cash Flow to Firm to Interest Expense		 -5.50 -4.67 -2.26 -3.40 -3.51 -8.81 0.00 0.00 -6.28 -10.37 -19.20
Operating Cash Flow to Interest Expense		 -8.75 -5.78 -8.59 -9.09 -12.15 -9.68 0.00 0.00 -11.09 -4.38 -1.79
Operating Cash Flow Less CapEx to Interest Expense		 -8.97 -6.10 -8.77 -9.41 -12.62 -9.84 0.00 0.00 -11.26 -4.69 -2.06
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.24 0.20 0.20 0.22 0.26 0.19 0.20 0.28 0.42 0.50 0.66
Accounts Receivable Turnover		 9.32 9.22 8.81 7.80 8.98 8.35 8.31 6.29 7.24 8.42 9.37
Inventory Turnover		 0.90 0.88 0.88 0.94 0.98 0.98 0.96 1.07 1.28 1.51 1.66
Fixed Asset Turnover		 4.92 4.87 4.90 5.00 4.85 4.89 5.42 6.63 8.57 11.54 15.35
Accounts Payable Turnover		 0.38 0.30 0.36 0.34 0.42 0.32 0.32 0.33 0.51 0.51 0.48
Days Sales Outstanding (DSO)		 39.15 39.57 41.45 46.77 40.67 43.70 43.92 58.04 50.39 43.37 38.97
Days Inventory Outstanding (DIO)		 406.86 415.29 412.53 387.01 374.26 373.16 381.88 342.39 285.99 242.40 219.33
Days Payable Outstanding (DPO)		 971.49 1,211.78 1,020.78 1,064.66 859.97 1,124.86 1,146.00 1,100.41 716.42 711.65 757.79
Cash Conversion Cycle (CCC)		 -525.47 -756.92 -566.79 -630.88 -445.04 -708.00 -720.20 -699.97 -380.04 -425.89 -499.49
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 103 -37 -30 -45 4.78 -69 -195 -150 24 141 135
Invested Capital Turnover		 3.29 22.22 16.12 -342.80 7.09 -7.57 -3.98 -6.21 57.86 31.53 -50.65
Increase / (Decrease) in Invested Capital		 14 -103 -102 -88 -98 -32 -165 -105 19 209 329
Enterprise Value (EV)		 4,449 9,881 12,032 12,021 13,714 17,012 29,300 36,229 34,566 22,493 24,335
Market Capitalization		 3,881 9,957 12,545 12,351 13,808 18,330 30,440 37,118 35,247 23,110 24,926
Book Value per Share		 ($3.13) $0.26 $2.81 $1.60 $0.55 $6.86 $4.47 $3.46 $3.27 $3.49 $3.33
Tangible Book Value per Share		 ($4.47) ($1.07) $1.67 $0.51 ($0.52) $5.81 $3.43 $2.37 $2.20 $2.44 $2.07
Total Capital		 698 1,210 1,438 1,389 1,204 1,788 1,485 1,280 1,247 1,301 1,281
Total Debt		 1,163 1,171 955 1,103 1,105 539 540 541 542 544 555
Total Long-Term Debt		 939 947 955 1,103 1,105 539 540 541 542 544 545
Net Debt		 568 -76 -513 -330 -94 -1,318 -1,140 -889 -681 -617 -592
Capital Expenditures (CapEx)		 4.68 6.78 3.69 6.77 10 3.48 2.42 17 3.48 6.26 5.63
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -34 -128 -77 -110 -36 -87 -165 -105 29 35 -26
Debt-free Net Working Capital (DFNWC)		 562 1,118 1,391 1,324 1,163 1,770 1,515 1,325 1,252 1,195 1,120
Net Working Capital (NWC)		 338 894 1,391 1,324 1,163 1,770 1,515 1,325 1,252 1,195 1,110
Net Nonoperating Expense (NNE)		 212 98 71 -83 83 103 114 105 56 12 38
Net Nonoperating Obligations (NNO)		 568 -76 -513 -330 -94 -1,318 -1,140 -889 -681 -617 -592
Total Depreciation and Amortization (D&A)		 5.38 5.18 4.89 5.17 5.65 6.10 6.02 7.62 7.08 7.37 11
Debt-free, Cash-free Net Working Capital to Revenue		 -10.67% -39.05% -22.52% -30.16% -9.45% -21.82% -37.00% -17.27% 3.50% 3.06% -1.74%
Debt-free Net Working Capital to Revenue		 178.15% 340.37% 405.49% 364.07% 305.35% 444.58% 338.82% 218.55% 152.78% 105.06% 73.71%
Net Working Capital to Revenue		 107.09% 272.07% 405.49% 364.07% 305.35% 444.58% 338.82% 218.55% 152.78% 105.06% 73.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.06) ($1.94) ($1.27) ($1.30) ($1.42) ($1.70) ($1.75) ($1.55) ($0.76) ($0.06) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 148.46M 154.70M 173.72M 164.04M 180.86M 189.30M 211.76M 199.01M 215.47M 217.35M 218.79M
Adjusted Diluted Earnings per Share		 ($1.06) ($1.94) ($1.27) ($1.30) ($1.42) ($1.70) ($1.75) ($1.55) ($0.76) ($0.06) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 148.46M 154.70M 173.72M 164.04M 180.86M 189.30M 211.76M 199.01M 215.47M 217.35M 218.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 148.60M 171.85M 178.90M 181.00M 182.14M 211.37M 213.27M 215.55M 216.75M 218.38M 219.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -110 -130 -139 -172 -161 -178 -183 -175 -140 -71 -57
Normalized NOPAT Margin		 -145.94% -143.51% -148.91% -164.35% -173.33% -165.45% -128.53% -66.25% -45.82% -16.67% -10.92%
Pre Tax Income Margin		 -207.29% -331.83% -234.96% -224.32% -275.44% -298.32% -259.02% -123.91% -52.98% -2.67% -18.62%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -6.86 -13.60 -10.23 -10.64 -11.50 -14.71 0.00 0.00 -7.67 -0.10 -4.33
NOPAT to Interest Expense		 -4.84 -9.51 -7.10 -7.48 -8.05 -10.31 0.00 0.00 -5.34 -0.05 -3.07
EBIT Less CapEx to Interest Expense		 -7.08 -13.92 -10.41 -10.96 -11.97 -14.87 0.00 0.00 -7.84 -0.41 -4.60
NOPAT Less CapEx to Interest Expense		 -5.06 -9.83 -7.27 -7.80 -8.52 -10.47 0.00 0.00 -5.52 -0.36 -3.34
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Insmed’s financial statements show a company transitioning from a development-stage biotechnology business toward a higher-revenue commercial operation. Revenue increased from $67.7 million in Q3 2022 to $425.5 million in Q2 2026. Growth accelerated notably in late 2025 and 2026, with Q2 2026 revenue rising approximately 40% from Q1 2026 and nearly quadrupling from Q2 2025.

Gross profitability has also improved. Gross margin was approximately 84% in Q2 2026, compared with about 74% in Q2 2025 and 80% in Q3 2025. However, Insmed remains unprofitable because selling, general and administrative costs and research and development spending totaled approximately $457.5 million in Q2 2026, exceeding gross profit of $358.3 million.

  • Revenue growth has accelerated sharply. Quarterly revenue rose from $90.3 million in Q2 2024 to $425.5 million in Q2 2026, indicating strong commercial momentum.
  • Gross margins are expanding. Q2 2026 gross profit of $358.3 million represented an approximately 84% gross margin, providing greater potential operating leverage as the business scales.
  • Quarterly losses have narrowed substantially. Net loss improved to $13.2 million in Q2 2026 from $163.6 million in Q1 2026 and $321.7 million in Q2 2025. Operating loss was only $1.5 million in Q2 2026, although special items contributed significantly to that result.
  • Liquidity remains substantial. Insmed held $544.8 million in cash and $615.5 million in short-term investments at June 30, 2026. After subtracting $543.5 million of long-term debt, the company still had approximately $616.8 million of net cash.
  • Balance-sheet equity has recovered. Total equity increased to $757.5 million in Q2 2026 from negative equity in 2023 and early 2024, supported by equity financing and improved financial resources.
  • Operating cash flow is improving but remains negative. Cash used in operations declined to $88.8 million in Q2 2026 from $222.7 million in Q1 2026 and $205.6 million in Q2 2025. The company nevertheless continues to consume cash from operations.
  • Investment activity materially affects reported cash trends. Insmed has frequently purchased and sold short-term investments, creating large swings in investing cash flow that do not necessarily represent changes in its underlying business performance.
  • Insmed has not yet achieved sustained profitability. Net losses have continued in every reported quarter shown, and Q2 2026 still produced a $13.2 million loss despite substantial revenue growth.
  • Research and development and selling expenses remain very high. Q2 2026 R&D expense was $210.0 million and SG&A expense was $247.5 million. These costs continue to absorb most of the company’s gross profit and delay consistent operating profitability.
  • Shareholder dilution has been significant. Weighted average basic shares increased from 120.8 million in Q3 2022 to 217.4 million in Q2 2026. While the larger share base has helped fund operations and development, it reduces each existing shareholder’s ownership percentage.

Overall, the statements point to a more promising operating trajectory: rapidly rising revenue, stronger gross margins, narrowing losses and a much healthier equity position. The key issue for investors is whether revenue growth can eventually outpace the company’s elevated R&D and commercial expenses before continued operating cash burn requires additional financing.

11/15/26 02:02 PM ETAI Generated. May Contain Errors.

Insmed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Insmed's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Insmed's net income appears to be on a downward trend, with a most recent value of -$1.28 billion in 2025, falling from -$118.18 million in 2015. The previous period was -$913.77 million in 2024. Find out what analysts predict for Insmed in the coming months.

Insmed's total operating income in 2025 was -$1.25 billion, based on the following breakdown:
  • Total Gross Profit: $483.49 million
  • Total Operating Expenses: $1.73 billion

Over the last 10 years, Insmed's total revenue changed from $0.00 in 2015 to $606.42 million in 2025, a change of 60,642,300,000.0%.

In the past 13 quarters, Insmed's cash and equivalents has ranged from $334.76 million in Q3 2025 to $1.28 billion in Q2 2025, and is currently $396.56 million as of their latest financial filing in Q3 2026.

Insmed had total debt of $540.96 million at the end of 2025, a 51.0% decrease from 2024, and a 2,051.8% increase since 2015.

Over the last 10 years, Insmed's book value per share changed from 5.04 in 2015 to 3.46 in 2025, a change of -31.3%.


Related Companies

Financial statements for NASDAQ:INSM last updated on 10/29/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...
TradeWins | Sponsoredtc pixel